213 related articles for article (PubMed ID: 38331849)
1. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.
Van den Eynde A; Gehrcken L; Verhezen T; Lau HW; Hermans C; Lambrechts H; Flieswasser T; Quatannens D; Roex G; Zwaenepoel K; Marcq E; Joye P; Cardenas De La Hoz E; Deben C; Gasparini A; Montay-Gruel P; Le Compte M; Lion E; Lardon F; Van Laere S; Siozopoulou V; Campillo-Davo D; De Waele J; Pauwels P; Jacobs J; Smits E; Van Audenaerde JRM
J Hematol Oncol; 2024 Feb; 17(1):8. PubMed ID: 38331849
[TBL] [Abstract][Full Text] [Related]
2. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
4. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
5. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
6. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies.
He B; Mai Q; Pang Y; Deng S; He Y; Xue R; Xu N; Zhou H; Liu X; Xuan L; Li C; Liu Q
Front Immunol; 2023; 14():1130442. PubMed ID: 37207215
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Expression of CD70 and POSTN in Cancer-Associated Fibroblasts Predicts Worse Survival of Colorectal Cancer Patients.
Komura M; Wang C; Ito S; Kato S; Ueki A; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Kasugai K; Takiguchi S; Takahashi S; Inaguma S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473788
[TBL] [Abstract][Full Text] [Related]
9. Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6.
Lee YE; Go GY; Koh EY; Yoon HN; Seo M; Hong SM; Jeong JH; Kim JC; Cho D; Kim TS; Kim SC; Jun E; Jang M
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849201
[TBL] [Abstract][Full Text] [Related]
10. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
11. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
[TBL] [Abstract][Full Text] [Related]
12. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
[TBL] [Abstract][Full Text] [Related]
13. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
14. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
[No Abstract] [Full Text] [Related]
16. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
17. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H; Pan W
Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
[TBL] [Abstract][Full Text] [Related]
18. CD27/CD70 interaction directly induces natural killer cell killing activity.
Yang FC; Agematsu K; Nakazawa T; Mori T; Ito S; Kobata T; Morimoto C; Komiyama A
Immunology; 1996 Jun; 88(2):289-93. PubMed ID: 8690463
[TBL] [Abstract][Full Text] [Related]
19. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract][Full Text] [Related]
20. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
